AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
GoodRx Holdings, Inc.
Video analysis: GDRX
All videosNo video analysis for this stock yet. Request one from our team.
News: GDRX
GoodRx Covers Whole Households and Pets in New Prescription Plan
Prescription platform GoodRx has launched a new plan that covers a primary member and up to four dependents, including children, adult family members and pets, the company said in a Thursday (Sept. 3) press release.
GoodRx offers health subscription for families, to launch as employee benefit in 2027
GoodRx, a prescription drug savings site, announced on Thursday a family healthcare subscription for access to common medical services and over 250 medications, and it plans to launch the program as part of employer health benefits in 2027.
From Kids to Canines: GoodRx Launches Companion Family Plan to Bring Healthcare Savings to the Whole Household
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the trusted platform for prescription access and affordability in the U.S., today launched the GoodRx Companion Family Plan, expanding its everyday healthcare subscription to the entire family, including pets. As widening coverage gaps and rising out-of-pocket costs leave households paying more for care, the new plan brings Companion's free and low-cost prescriptions and savings on common healthcare services together in one affordabl.
GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope
GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation reflects these improvements. I remain marginally more positive, yet GDRX still presents considerable risk, warranting a continued neutral rating.
Push for 'COMPETITIVE CASH PRICING': GoodRx CEO on TrumpRx partnership
GoodRx CEO Wendy Barnes discusses the company's partnership with TrumpRx and efforts to lower prescription drug costs on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #clamancountdown #goodrx #trumprx #wendybarnes #prescriptiondrugs #drugprices #healthcare #health #medicine #pharmacy #patients #consumer #trump #donaldtrump #donald_trump
GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript
GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript
GoodRx Q2 Earnings Call Highlights
GoodRx NASDAQ: GDRX reported second-quarter 2026 revenue of $200.4 million and adjusted EBITDA of $63.7 million, representing a 31.8% adjusted EBITDA margin, as growth in its Pharma Direct and subscription businesses offset pressure in prescription transaction revenue.
GoodRx and Oscar Health Tout Tech as Consumer Needs Change
The latest earnings from Oscar Health and GoodRx show both companies dealing with a changing customer base. The former company reported half-year earnings Thursday (Aug. 6) showing record profitability for the first six months of 2026, with revenues surging 70% to $4.9 billion.
